TITLE: NEDD9 Monoclonal Antibody Therapeutic for Pulmonary Thromboembolic Disease TYPE OF AWARD: Drive CLINICAL AREA:  Biologic INSTITUTION: Brigham and Women’s Hospital DESCRIPTION: Increased platelet-endothelial adhesion is a central pathobiological event underlying the pathogenesis of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Current therapies to treat thrombosis in PAH and CTEPH emphasize non-specific coagulation proteins, and are associated…

Read More

We are thrilled to share with you a new web video we are releasing that highlights our ‘Commercialization Coaches’ and other services that are ways B-BIC successfully differentiates from other grants. Kantum Pharma, dedicated to the prevention and treatment of Acute Kidney Injury, received its first B-BIC Pilot grant in 2017.

Read More

TITLE: Humanized anti-DEspR antibody therapy for acute respiratory distress syndrome TYPE OF AWARD: Drive CLINICAL AREA:  Lung INSTITUTION: Boston University DESCRIPTION: Acute respiratory distress syndrome (ARDS) and its progression to multi-organ failure (MOF) affects ~200,000 ICU patients each year in the US, with high mortality and healthcare costs. ARDS is driven by hyperinflammation-injury cycles that begin as a normal injury…

Read More

Over the course of 2019, our coaches and staff broke down the B-BIC application process to provide you with expert advice on all the of the questions we ask you to answer when applying for our program. For those who are not applying yet, the B-BIC proposal has many similarities to a business plan, which…

Read More

TITLE: PR1P, an inhaled novel short peptide for Acute Lung Injury and ARDS. TYPE OF AWARD: Drive TECHNOLOGY TYPE: Small Molecule CLINICAL AREA:  Lung INSTITUTION: Boston Children’s Hospital DESCRIPTION:ARDS is an acute inflammatory lung disease characterized by hypoxemia and multi-organ failure with mortality reaching 50%. It accounts for almost 200,000 ICU admissions yearly in the US and…

Read More

Written by Carl Berke, PhD. Partner at the Partners Innovation Fund Thomas Edison famously remarked, “Invention is 1% inspiration and 99% perspiration”. The Wizard of Menlo Park was a prolific inventor who never left his lab, but his intellectual property was adopted by a plethora of companies who translated his technology into products that delighted…

Read More

WATCH:  B-BIC’s Work With Platelet Biogenesis One of B-BIC’s first grant recipients was Jonathan Thon, a researcher based at Brigham and Women’s Hospital. Jonathan and his team had been researching two technologies necessary for producing platelets outside of the body. They had achieved promising results that demonstrated a microfluidic platform could simulate bone marrow physiological…

Read More

Potential for commercialization. Technology that addresses an unmet clinical need. Heart, Lung, Blood or Sleep indications. Preliminary data indicating promise of commercialization. Differentiation from competitors. IP filings, with institutions as the assignee. This event will provide you with the opportunity to pitch a team of experts on your research. You will receive immediate feedback with…

Read More

Keep pitch short and focused on the technology and its commercial application. Limit the discussion of preliminary results, and focus on the most relevant results with conclusions – not data. Present the science within the context of the business strategy. This event will provide you with the opportunity to pitch a team of experts on your research.…

Read More